NOT KNOWN FACTUAL STATEMENTS ABOUT GANDOTINIB

A single instance is the event in the BCR-ABL allosteric inhibitor GNF-2 that may overcome the outcome of resistant mutations and also exhibits an elevated potency when used in combination with traditional ATP-aggressive inhibitorsOther good reasons for discontinuation integrated adverse functions, affected individual selection, and progressive dis